A Multicenter, Open-label Study to Evaluate the Safety and Tolerability of LCZ696 Treatment in Japanese Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction After CLCZ696D2301 (PARAGON-HF)
Latest Information Update: 15 Dec 2021
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Novare Pharmaceuticals
Most Recent Events
- 03 Dec 2020 Status changed from recruiting to discontinued.
- 30 Mar 2020 Results (n=15,038) of meta-analysis exploring angioedema in the 6 clinical trials (PARADIGM-HF, PIONEER, TITRATION, EVALUATE-HF & PARAGON-HF) and in real-world pharmacovigilance data, presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology.
- 24 Sep 2019 Status changed from not yet recruiting to recruiting.